With recent emerging clinical evidence that supports the significant anti-tum or activity of single-agen t immunotherapies, combination therapies are now explored in an attempt to increase overall patient survival as exemplified by the combination therapy of anti-PD-1 and anti-CTLA-4 antibodies in patients with advanced melanoma. These findings raise the possibility that combining checkpoint blocking anti bodies with agonistic antibodies that targ et T-cell co-stimulat ory molecules could also be beneficial. In this study, participants with advanced tumors will be tr eated with BMS-986226 (an agonistic antibody targeting inducible T-cell co-stimulator [ICOS]) in monotherapy or in combination withnivolumab (BMS-936558, PD-1 r eceptor blocking monoclonal antibody [mAb]) or ipilimumab (BMS-734016/MDX010; a checkpoint blocking antibody that recognizes CTLA-4). Research hypothesis: It is anticipated that BMS-986226, anti-ICOS mAb, administered as single agent or in combination with nivolumab (BMS-936558/MDX, anti-PD-1 antibody) or ipilimumab (BMS-734016/MDX, anti-CTLA-4 anti body), w ill demonstr ate acceptable safety and tolerability and a favorable risk/benefit profile that w ill support further clinical testing. No prospective hypotheses are being formally evaluated in this study.